Sarepta Therapeutics Inc Expected to Earn Q1 2018 Earnings of ($0.45) Per Share (SRPT)
Sarepta Therapeutics Inc (NASDAQ:SRPT) – Equities research analysts at Leerink Swann issued their Q1 2018 earnings per share estimates for Sarepta Therapeutics in a research note issued to investors on Wednesday. Leerink Swann analyst J. Schwartz forecasts that the biotechnology company will earn ($0.45) per share for the quarter. Leerink Swann currently has a “Outperform” rating and a $66.00 target price on the stock. Leerink Swann also issued estimates for Sarepta Therapeutics’ FY2018 earnings at ($1.21) EPS and FY2019 earnings at $0.51 EPS.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The firm had revenue of $45.95 million during the quarter, compared to the consensus estimate of $41.29 million. During the same quarter in the prior year, the firm earned ($0.95) earnings per share.
Several other brokerages also recently commented on SRPT. Janney Montgomery Scott assumed coverage on shares of Sarepta Therapeutics in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $75.00 target price for the company. HC Wainwright set a $75.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Zacks Investment Research downgraded shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 5th. Oppenheimer reaffirmed a “buy” rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. Finally, UBS Group reaffirmed an “outperform” rating and issued a $56.51 target price (down previously from $76.00) on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $63.88.
Shares of Sarepta Therapeutics (NASDAQ SRPT) traded up $0.85 during trading hours on Monday, reaching $57.00. 91,473 shares of the company’s stock traded hands, compared to its average volume of 2,576,267. Sarepta Therapeutics has a 1 year low of $26.26 and a 1 year high of $59.95. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52. The company has a market capitalization of $3,630.00, a P/E ratio of -27.94 and a beta of 1.37.
In other news, SVP Shamim Ruff sold 10,000 shares of the firm’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $55.00, for a total transaction of $550,000.00. Following the completion of the sale, the senior vice president now owns 37,045 shares in the company, valued at approximately $2,037,475. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $55.89, for a total transaction of $372,618.63. Following the completion of the sale, the director now owns 13,333 shares of the company’s stock, valued at approximately $745,181.37. The disclosure for this sale can be found here. Company insiders own 9.60% of the company’s stock.
A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Sarepta Therapeutics by 4.0% in the 2nd quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock worth $143,572,000 after purchasing an additional 162,543 shares in the last quarter. HealthCor Management L.P. raised its stake in Sarepta Therapeutics by 31.1% in the 2nd quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after purchasing an additional 481,890 shares in the last quarter. Jennison Associates LLC raised its stake in Sarepta Therapeutics by 103.9% in the 3rd quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock worth $51,885,000 after purchasing an additional 582,894 shares in the last quarter. Eagle Asset Management Inc. raised its stake in Sarepta Therapeutics by 26.0% in the 3rd quarter. Eagle Asset Management Inc. now owns 1,006,222 shares of the biotechnology company’s stock worth $49,858,000 after purchasing an additional 207,810 shares in the last quarter. Finally, Emerald Advisers Inc. PA raised its stake in Sarepta Therapeutics by 2.1% in the 3rd quarter. Emerald Advisers Inc. PA now owns 893,484 shares of the biotechnology company’s stock worth $40,528,000 after purchasing an additional 18,077 shares in the last quarter. Institutional investors and hedge funds own 82.02% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Sarepta Therapeutics Inc Expected to Earn Q1 2018 Earnings of ($0.45) Per Share (SRPT)” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/sarepta-therapeutics-inc-expected-to-earn-q1-2018-earnings-of-0-45-per-share-srpt/1801250.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.